[Initial experience with preorally administered dipotassium clorazepate and tilidine-naloxone in extracorporeal shockwave lithotripsy].
After 70 treatments with extracorporeal shock wave lithotripsy (ESWL), using a combination of dipotassiumclorazepate p.o. 12 h before treatment and tilidin-naloxon 45 min before ESWL, 56 patients reported to be painfree or only minor, well-tolerable pain. Informed consent was obtained in all patients for this pilot study, leaving the possibility of further pain medication. 7 patients asked for an additional analgesic (fentanyl) and another 7 patients required a sedative (midazolam). No further anesthesiologic procedures were necessary. Nausea was observed in one patient as a possible side-effect of tilidin. To confirm these preliminary results, a prospective randomized study is currently conducted.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D003009:Clorazepate Dipotassium / Q000008:administration & dosage / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004824:Epidural Space; D005260:Female; D006801:Humans; D007267:Injections; D008096:Lithotripsy; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy*; D013993:Tilidine / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D003509:Cyclohexanecarboxylic Acids; D009270:Naloxone; D003009:Clorazepate Dipotassium; D013993:Tilidine
Erste Erfahrungen mit der peroralen Gabe von Dikaliumclorazepat und Tilidin-Naloxon zur extrakorporalen Stosswellenlithotripsie.